Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
HUMAthis companyHumacyte, Inc.	$0.48	-3.69×	48.86×	74.54×	-7.48×	-105.8%	-736.5%	-5271.7%	-2003.6%	-1313.4%	-107.0%	-69.7%	20.86×	-0.65×	-9.55×	3.69×	0.0%	3	-8.67	1	D+
ACHVAchieve Life Sciences, Inc.	$6.55	-3.98×	10.07×	0×	-3.93×	-98.2%	0.0%	0.0%	0.0%	-254.0%	-150.5%	-22.8%	0.69×	0.11×	-67.01×	4.39×	0.0%	2	-2.57	2	C
ARCTArcturus Therapeutics Holdings Inc.	$10.42	-2.55×	0.78×	2.5×	0.61×	-144.1%	95.5%	-111.5%	-97.9%	-30.7%	-31.4%	-44.2%	0.12×	3.28×	0×	6.64×	0.0%	1	-0.72	2	C
AVIRAtea Pharmaceuticals, Inc.	$4.40	-1.84×	1.06×	0×	-1.19×	-75.3%	0.0%	0.0%	0.0%	-57.5%	-63.0%	-45.4%	0×	0.58×	0×	7.82×	0.0%	2	1.99	3	B-
FHTXFoghorn Therapeutics Inc.	$1.98	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
IMRXImmuneering Corporation	$3.62	-5.18×	1.33×	0×	-2.96×	-19.7%	0.0%	0.0%	0.0%	-25.6%	-26.7%	-15.7%	0.02×	2.24×	0×	17.5×	0.0%	0	6.81	2	B-
Peer median	—	-3.98×	1.06×	0×	-2.96×	-98.2%	0.0%	0.0%	0.0%	-30.7%	-58.9%	-25.3%	0.02×	0.58×	0×	6.64×	0.0%	2	-0.72	2	—